Microdosing News and Research

RSS

Study finds microdosing LSD leads to longer sleep: Insights from a controlled trial

A phase I trial to assess the effect of micro-dosing of lysergic acid diethylamide (LSD) on the sleep.

17 Apr 2024

The therapeutic effects and safety of psychedelics

Psychedelics are reported to have rapid-onset and long-lasting therapeutic benefits after a single or few doses.

14 Dec 2022

Psilocybin microdosing associated with mood and mental health improvements

The latest study to examine how tiny amounts of psychedelics can impact mental health provides further evidence of the therapeutic potential of microdosing.

11 Jul 2022

Placebo-like effects may explain the benefits of psychedelic drugs

Positive psychological effects associated with taking small doses of psychedelic drugs are likely the result of users' expectations, suggests a study published today in eLife.

3 Mar 2021

New microneedle patches for delivery of psychedelic pharmaceuticals

Although one may think of psychedelic pharmaceuticals as being dangerous and detrimental, scientists have been conducting experiments and clinical trials on some of them and have obtained positive results when testing them for medical use.

23 Feb 2021

Antibiotic combined with measurement technology may save time and money in developing new active ingredients

A minimal – and therefore innocuous – dose of an antibiotic coupled with highly sensitive measurement technology could save time and money in the development of new active ingredients.

7 May 2020

New ‘microdose’ psychedelic treatment appears to relieve anxiety and depression

Lava lamps, tambourines and, of course, psychedelic drugs were hallmarks of the 1960s. Psychedelic drugs can make people euphoric, though users can also become extremely anxious and agitated. But that's at a high dose.

5 Mar 2019

Study looks at effects of microdosing of psychedelics on mental health

Microdosing of psychedelic substances involves taking very small doses of a psychedelic drug such as LSD or psilocybin (magic mushrooms) over weeks or even months. There have been anecdotal claims that such microdosing can improve health and also performance and relationships. These earlier studies dealt with the one time effect of microdosing.

6 Feb 2019

Toxicological evaluation and dosimetry estimation of potential PET radiotracer

The SR101 N-(3-[18F]Fluoropropyl) sulfonamide ([18F]SRF101) is a Sulforhodamine 101 derivative that was previously synthesized by our group.

25 Sep 2018

New eyedropper delivers medication more precisely with less waste and reduced side effects

A new kind of eyedropper can deliver tiny droplets of medication, treating the eye more precisely than traditional eyedroppers, while reducing waste and avoiding dangerous side effects.

14 Nov 2017

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Update on microdosing

One of yesterday's most promising new tools for speeding the development of new medicines - "microdosing" - has found niches in that process today, and they include uses unanticipated a decade ago.

23 Jan 2013

Technology to determine most effective chemotherapy treatment wins first prize in UC Davis Big Bang! competition

A technology that could allow cancer specialists to better determine the most effective chemotherapy treatment for a given patient won the $10,000 in first prize money in the 11th annual Big Bang! Business Plan Competition at the University of California, Davis. The contest is run by MBA students in the Graduate School of Management.

20 May 2011

Celerion completes Clean Room, pharmacist certification to comply with USP 797 guidelines

Celerion, the premier provider of innovative early stage drug development solutions, announces the completion of a Clean Room and pharmacist certification to comply with USP 797 guidelines.

3 Mar 2011

QPS acquires Xendo Drug Development

QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development BV (XDD), headquartered in Groningen, The Netherlands. XDD, a European contract research organization (CRO), will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC.

26 Jul 2010

Quintiles opens expanded research facility in London

Quintiles today announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.

8 Mar 2010

Chlorophyll and chlorophyllin effective in limiting aflatoxin absorption in humans

A new study has found that chlorophyll and its derivative chlorophyllin are effective in limiting the absorption of aflatoxin in humans. Aflatoxin is produced by a fungus that is a contaminant of grains including corn, peanuts and soybeans; it is known to cause liver cancer - and can work in concert with other health concerns, such as hepatitis.

30 Dec 2009

Petition aims to stem the flood of dangerous drugs reaching Americans

In a petition filed with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.

15 Nov 2007

Injection of EU funds for a microdose project

A new EU-funded project kicked off this month which aims to bridge the gap between the laboratory and the clinic. The EU Microdose AMS Partnership Programme (EUMAPP) aims to boost Europe’s expertise in micodosing and its application of AMS, or accelerator mass spectrometry, to developing new candidate drugs for treating diseases the world over.

23 Jan 2006

Functional genomics and proteomics may accelerate the discovery of new drugs and therapeutic molecules

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.

29 Apr 2004